Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Hidalgo M, et al. Among authors: silberman s. J Clin Oncol. 2001 Jul 1;19(13):3267-79. doi: 10.1200/JCO.2001.19.13.3267. J Clin Oncol. 2001. PMID: 11432895 Clinical Trial.
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA, Spira AI, Tsai ML, Samuëlsz E, Silberman SL, Erlander M, Wang ES. Zeidan AM, et al. Among authors: silberman sl. Clin Cancer Res. 2020 Dec 1;26(23):6132-6140. doi: 10.1158/1078-0432.CCR-20-2586. Epub 2020 Sep 30. Clin Cancer Res. 2020. PMID: 32998961 Clinical Trial.
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: silberman s. J Clin Oncol. 2003 Dec 1;21(23):4342-9. doi: 10.1200/JCO.2003.04.190. J Clin Oncol. 2003. PMID: 14645423 Clinical Trial.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Demetri GD, et al. Among authors: silberman sl. N Engl J Med. 2002 Aug 15;347(7):472-80. doi: 10.1056/NEJMoa020461. N Engl J Med. 2002. PMID: 12181401 Free article. Clinical Trial.
Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, Kowalski MO, Sayles D, Dimitrijevic S, Fletcher C, Hornick J, Salgia R, Le Chevalier T. Johnson BE, et al. Among authors: silberman s. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5880-7. Clin Cancer Res. 2003. PMID: 14676110 Clinical Trial.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA. Heinrich MC, et al. Among authors: silberman s. J Clin Oncol. 2023 Nov 1;41(31):4829-4836. doi: 10.1200/JCO.22.02771. J Clin Oncol. 2023. PMID: 37890277 Clinical Trial.
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. van Oosterom AT, et al. Among authors: silberman s. Lancet. 2001 Oct 27;358(9291):1421-3. doi: 10.1016/s0140-6736(01)06535-7. Lancet. 2001. PMID: 11705489 Clinical Trial.
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NC, Goldman JM. Apperley JF, et al. Among authors: silberman s. N Engl J Med. 2002 Aug 15;347(7):481-7. doi: 10.1056/NEJMoa020150. N Engl J Med. 2002. PMID: 12181402 Free article.
186 results